HC Wainwright Issues Pessimistic Forecast for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price
Cartesian Therapeutics (NASDAQ:RNAC – Free Report) had its target price lowered by HC Wainwright from $45.00 to $40.00 in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. RNAC has been the subject of a number of other research reports. BTIG Research assumed coverage on shares of […]
Cartesian Therapeutics (NASDAQ:RNAC – Free Report) had its target price lowered by HC Wainwright from $45.00 to $40.00 in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. RNAC has been the subject of a number of other research reports. BTIG Research assumed coverage on shares of […]
